IFNB1 and myeloid sarcoma: Clinically effective IFN-β therapy was associated with a downregulation of proliferative T-cell responses to EBNA-1 and showed efficacy in reducing pHERV-W and HHV6-A plasma viral loads, two additional viral risk factors in the context of MS, as will be described further below (132, 133).